New chemo delivery method aims to shrink untreatable colon tumors
NCT ID NCT07333053
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests a procedure called transarterial infusion chemotherapy (TAIC) for people with colorectal cancer that cannot be removed by surgery. Instead of giving chemo through a vein, TAIC delivers it directly to the tumor's blood supply, which may boost effectiveness and reduce side effects. The trial will enroll 30 participants and compare TAIC plus targeted drugs to standard intravenous chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (FOLFOX) plus either cetuximab or bevacizumab
- What this could lead to
- If it works, this could offer a more effective and less toxic treatment option for people with colorectal cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The procedure is invasive and carries risks like bleeding or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
RECRUITINGXicheng, Beijing Municipality, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.